April Swoner, NP
Family · Hermitage, TNNPI 1972007201
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $184,497 of the $246,466 with a category attached, or 74.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 20.9%. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,133 payments — averaging $115.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$52K
- Acadia Pharmaceuticals Inc$38K
- Biohaven Pharmaceuticals, Inc.$33K
- Biohaven Pharmaceutical Holding Company Ltd.$26K
- ANI Pharmaceuticals, Inc.$25K
- Amgen$16K
- plus $56K from 54 others
What the payments were for
- Consulting fees$1,1000%
- Speaking & faculty fees$184,49775%
- Travel & lodging$15,1946%
- Food & beverage$45,32018%
- Education$3560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$246,466 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 44 | $219,346 |
| UbrelvyUbrogepant | 79 | $130,176 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 21 | $105,896 |
| QuliptaAtogepant | 91 | $102,340 |
| Kesimpta PenOfatumumab | 12 | $100,081 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $96,747 |
| Nurtec OdtRimegepant Sulfate | 45 | $90,671 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 15 | $65,710 |
| BotoxOnabotulinumtoxina | 48 | $63,209 |
| Aimovig AutoinjectorErenumab-Aooe | 34 | $53,117 |
| GocovriAmantadine Hcl | 12 | $40,518 |
| RytaryCarbidopa/Levodopa | 30 | $31,032 |
| NuedextaDextromethorphan Hbr/Quinidine | 16 | $27,989 |
| NourianzIstradefylline | 13 | $25,882 |
| BriviactBrivaracetam | 15 | $21,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $51,619 | $295,725218 claims |
| Acadia Pharmaceuticals IncNuplazid | $38,192 | $219,34644 claims |
| PfizerOctagam, Nurtec Odt, Eliquis, Dilantin | $9,546 | $217,91197 claims |
| CSL BehringPrivigen | $422 | $96,74714 claims |
| MDD US Operations, LLCGocovri | $6,457 | $40,51812 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $250 | $32,14341 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $295 | $27,98916 claims |
| Kyowa Kirin, Inc.Nourianz | $140 | $25,88213 claims |
| UCB, Inc.Briviact | $3,278 | $21,37415 claims |
| Neurocrine Biosciences, Inc.Ongentys | $1,941 | $15,47316 claims |
| Upsher-smith Laboratories LLCTopiramate | $649 | $3,184121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Hermitage
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
- Melissa RikalNashville$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.